title: [Therapy of chronic inflammatory bowel diseases. Standards, controversies and perspectives].
abstract: Crohn's disease and ulcerative colitis are the most common forms of chronic inflammatory bowel disease. The therapeutic algorithm is complex and individualized especially in complicated courses of the disease. This article gives a comprehensive overview on the typical courses of disease and the standard therapy of both diseases. Furthermore, ongoing controversies will be highlighted including early immunosuppression and immunomodulation as well as new therapeutic goals, such as mucosal healing. Finally, a perspective on future therapeutic options is given focusing especially on vedolizumab, the new antibody against the bowel-specific α4β7-integrin.
authors.affiliation: Abteilung Innere Medizin 1, Asklepios Klinik Nord, Standort Heidberg, Tangstedter Landstr. 400, 22417, Hamburg, Deutschland, k.herrlinger@asklepios.com.
authors.forename: K
authors.initials: K
authors.lastname: Herrlinger
authors.forename: K
authors.initials: K
authors.lastname: Fellermann
authors.forename: E F
authors.initials: EF
authors.lastname: Stange
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D002908:Chronic Disease; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C543529:vedolizumab; D001379:Azathioprine